Federal Register / Vol. 75, No. 103 / Friday, May 28, 2010 / Notices 30045 

plans to date, including the NORA 

Construction, Manufacturing, Public 

Safety, Services, and Wholesale and 

Retail Trade Councils. Updates will also 

be given on cross-sector activities in the 

areas of Healthy People 2020 and the 

WorkLife Initiative. After each update, 

there will be time to discuss partnership 

opportunities. 

Status: The meeting is open to the 

public, limited only by the capacities of 

the conference call and conference room 

facilities. There is limited space 

available in the meeting room (capacity 

34). Therefore, information to allow 

participation in the meeting through the 

internet (to see the slides) and a 

teleconference call (capacity 50) will be 

provided to registered participants. 

Participants are encouraged to consider 

attending by this method. Each 

participant is requested to register for 

the free meeting by sending an e-mail to 

noracoordinator@cdc.gov containing the 

participant’s name, organization name, 

contact telephone number on the day of 

the meeting, and preference for 

participation by Web meeting 

(requirements include: Computer, 

internet connection, and telephone, 

preferably with ‘mute’ capability) or in 

person. An e-mail confirming 

registration will include the details 

needed to participate in the Web 

meeting. Non-US citizens are 

encouraged to participate in the web 

meeting. Non-US citizens who do not 

register to attend in person on or before 

June 2, 2010, will not be granted access 

to the meeting site and will not be able 

to attend the meeting in-person due to 

mandatory security clearance 

procedures at the Patriots Plaza facility. 

Background: NORA is a partnership 

program to stimulate innovative 

research in occupational safety and 

health leading to improved workplace 

practices. Unveiled in 1996, NORA has 

become a research framework for the 

nation. Diverse parties collaborate to 

identify the most critical issues in 

workplace safety and health. Partners 

then work together to develop goals and 

objectives for addressing those needs 

and to move the research results into 

practice. The NIOSH role is facilitator of 

the process. For more information about 

NORA, see http://www.cdc.gov/niosh/ 

nora/about.html. 

Since 2006, NORA has been 

structured according to industrial 

sectors. Eight major sector groups have 

been defined using the North American 

Industrial Classification System 

(NAICS). After receiving public input 

through the web and town hall 

meetings, ten NORA Sector Councils 

have been working to define sectorspecific strategic plans for conducting 

research and moving the results into 

widespread practice. During 2008–2009, 

most of these Councils have posted draft 

strategic plans for public comment. 

Seven have posted finalized National 

Sector Agendas after considering 

comments on the drafts. For more 

information, see the link above and 

choose ‘‘Sector-based Approach,’’ 

‘‘NORA Sector Councils,’’ ‘‘Sector 

Agendas’’ and ‘‘Comment on Draft Sector 

Agendas’’ from the right-side menu. 

FOR FURTHER INFORMATION CONTACT: 

Sidney C. Soderholm, PhD, NORA 

Coordinator, E-mail 

noracoordinator@cdc.gov, telephone 

(202) 245–0665. 

Dated: May 20, 2010. 

Tanja Popovic, 

Deputy Associate Director for Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2010–12743 Filed 5–27–10; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Oncologic Drugs Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Oncologic Drugs 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on July 20, 2010, from 8 a.m. to 3 

p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, The Ballrooms, 620 

Perry Pkwy., Gaithersburg, MD. The 

hotel telephone number is 301–977– 

8900. 

Contact Person: Nicole Vesely, c/o 

Melanie Whelan, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 51, rm. 6100, Silver Spring, 

MD 20993–0002, FAX: 301–847–8737, 

to reach by telephone before June 8, 

2010, please call 301–827–7001; to 

reach by telephone after June 8, 2010, 

please call 301–796–9001, e-mail: 

nicole.vesely@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512542. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On July 20, 2010, the 

committee will discuss supplemental 

biologics license applications (sBLAs) 

125085/191 and 192 for AVASTIN 

(bevacizumab), manufactured by 

Genentech, Inc. The two proposed 

indications (uses) for this product are: 

(1) First-line treatment of a subgroup of 

women with metastatic breast cancer 

known as HER2-negative breast cancer, 

in combination with the chemotherapy 

drug docetaxel; and (2) first-line 

treatment of HER2-negative metastatic 

breast cancer in combination with one 

of two classes of chemotherapy drugs, 

known as taxanes and anthracyclines, or 

with the chemotherapy drug, 

capecitabine. In addition to the 

discussion of these two indications, the 

committee will also consider the impact 

of the submitted studies on the 

conversion from accelerated to regular 

approval of the indication for the 

treatment, in combination with the 

chemotherapy drug paclitaxel, of 

patients who have not received 

chemotherapy for their locally recurrent 

or metastatic HER2 negative breast 

cancer. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before July 6, 2010. Oral 

presentations from the public will be 

scheduled between approximately 12:30 

p.m. to 1:30 p.m. Those desiring to 

make formal oral presentations should 


jlentini on DSKJ8SOYB1PROD with NOTICES
30046 Federal Register / Vol. 75, No. 103 / Friday, May 28, 2010 / Notices 

notify the contact person and submit a 

brief statement of the general nature of 

the evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before June 25, 2010. Time allotted 

for each presentation may be limited. If 

the number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by June 28, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Nicole 

Vesely at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: May 25, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–12870 Filed 5–27–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Review of proposals 

received in response to NIH–NHLBI–HB–11– 

02. 

Date: June 22, 2010. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

3137, Bethesda, MD 20817 (Telephone 

Conference Call) . 

Contact Person: Quirijn Vos, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, 301–451–2666, 

qvos@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Genetics Autoimmunity. 

Date: June 22, 2010. 

Time: 12 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Telephone Conference Call) . 

Contact Person: Sujata Vijh, PhD, Scientific 

Review Officer, Scientific Review Program, 

Division of Extramural Activities, NIAID/ 

NIH/DHHS, 6700B Rockledge Drive, MSC 

7616, Bethesda, MD 20892, 301–594–0985, 

vijhs@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: May 24, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–12942 Filed 5–27–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development Initial 

Review Group; Biobehavioral and Behavioral 

Sciences Subcommittee. 

Date: June 23–24, 2010. 

Time: 9 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Washington Plaza Hotel, 10 Thomas 

Circle, Washington, DC 20005. 

Contact Person: Marita R. Hopmann, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, NIH, 6100 Executive 

Blvd., Room 5b01, Bethesda, MD 20892, 301– 

435–6911, hopmannm@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: May 24, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–12940 Filed 5–27–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–2316–N] 

DEPARTMENT OF LABOR 

Employee Benefits Security 

Administration 

Medicaid and CHIP Programs; Meeting 

of the CHIP Working Group—June 14, 

2010 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), Department 

of Health and Human Services (DHHS); 

Employee Benefits Security 

Administration (EBSA), Department of 

Labor (DOL). 

ACTION: Notice. 

SUMMARY: This notice announces the 

second meeting of the Medicaid, 

Children’s Health Insurance Program 

(‘‘CHIP’’), and Employer-Sponsored 

Coverage Coordination Working Group 


jlentini on DSKJ8SOYB1PROD with NOTICES